SK Plasma, Infrastructure Investment Agreement with Andong City for Plasma Fractionation Products

[Financial News]  SK Plasma is expanding its storage facilities for the stable supply of plasma fractionation products in collaboration with Andong City.
SK Plasma announced on the 15th that it signed a memorandum of understanding (MOU) for an investment of about 12 billion won with Andong City at the Andong City Hall Communication Room on the 14th.
This agreement was promoted to enhance the stability of supply and operational efficiency in response to rapidly changing market demands through the expansion of storage facilities at the Andong Plant, while also contributing to the revitalization of the local economy and job creation.
According to the MOU, SK Plasma plans to sequentially invest more than 12 billion won by 2027 to establish freezing facilities for storing raw plasma and refrigeration facilities for finished pharmaceuticals on a site near the existing Andong Fractionation Center (7955.7㎡). Facilities to enhance production and operational efficiency, such as material warehouses and office spaces, are also expected to be established.
With the expansion of facilities, related new recruitment is expected to take place, and Andong City expects this investment to have an employment creation effect.
SK Plasma started construction of a plant in the Andong Gyeongbuk Bio Industry Complex in 2015 and began full-scale commercial production in 2018. This plant is equipped with production facilities capable of fractionating 600,000L of plasma annually and produces essential pharmaceuticals such as albumin and immunoglobulin for domestic and international supply.
Andong Mayor Kwon Ki-chang said, “This additional investment by SK Plasma is a turning point to enhance the competitiveness of the local bio industry and an important driving force for sustainable growth,” adding, “We plan to further strengthen cooperative relationships through creating a favorable environment for corporate growth and administrative support.”
Kim Seung-joo, CEO of SK Plasma, said, “The increase in storage facilities has created conditions to more flexibly produce and supply blood products in response to market demand changes,” adding, “We will continue various collaborations with Andong City to realize the stabilization of blood product supply and the revitalization of the local bio industry.”
Meanwhile, SK Plasma is constructing a plasma fractionation center with a processing capacity of 600,000L annually in the Karawang region of Indonesia, aiming to start operations in the fourth quarter of 2026. To minimize the supply gap of blood products before the plant becomes operational, it plans to import plasma secured in Indonesia to Korea for supply through a consignment production method at the Andong Plant.

vrdw88@fnnews.com Kang Joong-mo Reporter